Help

BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

Employee Benefits

Panel finds irregularities in FDA approval of costly Alzheimer’s drug

December 30, 2022 Reprints

An 18-month congressional investigation found the Food and Drug Administration didn't follow its own guidance and inappropriately collaborated with drugmaker Biogen before the approval of controversial Alzheimer's drug Aduhelm last year, Axios reports. The findings, released in a report Dec. 29 by the House Oversight and Energy and Commerce committees, come as the FDA reviews two other Alzheimer's drugs that target proteins believed to contribute to the development of Alzheimer's.

Help

Panel finds irregularities in FDA approval of costly Alzheimer’s drug

Readers Poll

Most Read in Employee Benefits

Sign up now for free access to this article and much more.

If you are already registered with Business Insurance, click here to Login

Please tell us a bit more about yourself in order to continue

About

Advertise

Reprints and Licensing

Resources